Trademark Overview
On Wednesday, June 18, 2025, a trademark application was filed for TANGRAM with the United States Patent and Trademark Office. The USPTO has given the TANGRAM trademark a serial number of 99240392. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Wednesday, June 18, 2025. This trademark is owned by E-THERAPEUTICS PLC. The TANGRAM trademark is filed in the Pharmaceutical Products, Treatment & Processing of Materials Services, Computer & Software Products & Electrical & Scientific Products, and Computer & Software Services & Scientific Services categories with the following description:
Custom manufacture of pharmaceutical and medical preparations; custom manufacture of pharmaceutical and medical preparations for use in targeting genes and blocking, silencing or inhibiting gene expression; custom manufacture of RNAi-based pharmaceuticals and medicines; custom manufacture of short interfering RNA (siRNA) medicines; custom manufacture of nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression; custom manufacture of pharmaceutical and medical preparations for use in targeting messenger RNA (mRNA) and triggering its degradation; provision of information, advice and consultancy services relating to all of the aforesaid.
Computer software; downloadable computer software; computer software for use in the field of pharmaceuticals, medicines and drug discovery; artificial intelligence and machine learning software; artificial intelligence and machine learning software for use in the field of pharmaceuticals, medicines and drug discovery; databases; electronic databases for use in the field of pharmaceuticals, medicines and drug discovery; computer platform software; computer software platforms; computer platform software platforms for use in the field of pharmaceuticals, medicines and drug discovery; computer software platforms for use in the field of pharmaceuticals, medicines and drug discovery.
Pharmaceutical and medical preparations; pharmaceutical and medical preparations for use in targeting genes and silencing or inhibiting gene expression; RNAi-based medicines and pharmaceuticals; short interfering RNA (siRNA) medicines and pharmaceuticals; nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression; pharmaceutical and medical preparations for use in targeting messenger RNA (mRNA) and triggering its degradation.
Scientific research and development; pharmaceutical research and development services; drug discovery services; human genetic research; scientific and technical data analysis in the field of pharmaceuticals, medicines and drug discovery; design, development, creation and maintenance of computer software platforms and computer software for use in the field of pharmaceuticals, medicines and drug discovery; Platform as a Service (PaaS) featuring computer software platforms for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating pharmaceutical and medical preparations, for use in the field of pharmaceuticals, medicines and drug discovery; design and development of computer-simulated models; Software as a Service (SaaS); provision of information, advice and consultancy services relating to all of the aforesaid.
